LOGIN KOREAN
About Us
Our Team
Professional Competence
IP1 Street
NEWS
How to Get Here
닫기

NEWS

SYP Co-CEO James Kyoungshik Shim Presents Strategic Valuation Models f…

Page info

Name admin Views 27 Datetime 26-11-13 16:40

On October 28, James Kyoungshik Shim, Co-CEO of SYP, delivered a keynote presentation titled "Technology Valuation for Advanced Regenerative Medicine: Valuation Models and Case Studies" at the '2026 RMAF Annual Symposium' held at the Peace & Park Convention in Yongsan, Seoul.

Hosted by the Ministry of Health and Welfare and the Regenerative Medicine Promotion Foundation under the theme "Innovation in Advanced Regenerative Medicine and Patient Access," the symposium brought together industry leaders and researchers. During his session, Shim emphasized that technology valuation reports should not be viewed merely as a final monetary figure, but rather utilized as a strategic tool for investor relations (IR), technology licensing negotiations, and government R&D proposals.

Key strategic insights from the presentation include:

  • Strategic Utilization of Core Valuation Pillars: Leveraging detailed analyses across four dimensions—Technology (competing technologies and indication expansion), Rights (patent scope and IP risks), Marketability (market size and entry feasibility), and Commercialization (clinical/regulatory timelines and cost structures)—to substantiate IR decks and R&D grant applications.

  • Data-Driven Licensing Negotiations: Extracting benchmark royalty rates, upfront payments, and milestone structures from real-world comparable transactions via databases such as the U.S. SEC EDGAR system to establish objective negotiation scenarios.

  • Regenerative Medicine-Specific rNPV Modeling: Refining the traditional risk-adjusted Net Present Value (rNPV) framework by sub-categorizing preclinical stages to accurately reflect human clinical research data and IND approvals, while advocating for continuous re-valuation as clinical milestones progress.

  • Impact of Commercialization Capabilities: Highlighting that the ultimate valuation of identical technologies varies significantly depending on a company’s manufacturing infrastructure, clinical execution capabilities, and distribution channels.

As a government-designated technology valuation institution, commercialization specialist, technology trading agency, and registered accelerator, SYP plans to continue supporting advanced regenerative medicine and bio-health startups in translating validated technology valuations into tangible fundraising and global licensing milestones.